NO982785L - Kromosom 13-koblet brystkreftmottagelighetsgen - Google Patents

Kromosom 13-koblet brystkreftmottagelighetsgen

Info

Publication number
NO982785L
NO982785L NO982785A NO982785A NO982785L NO 982785 L NO982785 L NO 982785L NO 982785 A NO982785 A NO 982785A NO 982785 A NO982785 A NO 982785A NO 982785 L NO982785 L NO 982785L
Authority
NO
Norway
Prior art keywords
breast cancer
relates
gene
human
brca2
Prior art date
Application number
NO982785A
Other languages
English (en)
Norwegian (no)
Other versions
NO982785D0 (no
Inventor
Sean V Tavtigian
Alexander Kamb
Jacques Simard
Fergus Couch
Johanna M Rommens
Barbara L Weber
Original Assignee
Myriad Genetics Inc
Univ Pennsylvania
Hsc Res Dev Lp
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27541925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO982785(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/639,501 external-priority patent/US5837492A/en
Application filed by Myriad Genetics Inc, Univ Pennsylvania, Hsc Res Dev Lp, Endorecherche Inc filed Critical Myriad Genetics Inc
Publication of NO982785D0 publication Critical patent/NO982785D0/no
Publication of NO982785L publication Critical patent/NO982785L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO982785A 1995-12-18 1998-06-17 Kromosom 13-koblet brystkreftmottagelighetsgen NO982785L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57377995A 1995-12-18 1995-12-18
US57535995A 1995-12-20 1995-12-20
US57655995A 1995-12-21 1995-12-21
US58539196A 1996-01-11 1996-01-11
US08/639,501 US5837492A (en) 1995-12-18 1996-04-29 Chromosome 13-linked breast cancer susceptibility gene
PCT/US1996/019598 WO1997022689A1 (en) 1995-12-18 1996-12-17 Chromosome 13-linked breast cancer susceptibility gene

Publications (2)

Publication Number Publication Date
NO982785D0 NO982785D0 (no) 1998-06-17
NO982785L true NO982785L (no) 1998-08-17

Family

ID=27541925

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982785A NO982785L (no) 1995-12-18 1998-06-17 Kromosom 13-koblet brystkreftmottagelighetsgen

Country Status (11)

Country Link
US (2) US6033857A (de)
EP (1) EP0785216B2 (de)
JP (1) JP3455228B2 (de)
AT (1) ATE230759T1 (de)
AU (1) AU1461597A (de)
CA (1) CA2239733C (de)
DE (1) DE69625678T3 (de)
IL (1) IL124620A0 (de)
NO (1) NO982785L (de)
NZ (1) NZ326525A (de)
WO (1) WO1997022689A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838256B2 (en) 1996-02-12 2005-01-04 Gene Logic Inc. Coding sequences of the human BRCA1 gene
US20030022184A1 (en) * 1996-02-12 2003-01-30 Oncormed. Inc. Coding sequences of the human BRCA1 gene
EP1012577A4 (de) 1996-12-03 2004-08-04 Michael R Swift Prädisposition für brustkrebs durch mutationen die die position des ataxialangiectasia gens beeinflussen
GB9708221D0 (en) * 1997-04-23 1997-06-11 Cancer Res Campaign Tech Substances and uses thereof
JP2001514887A (ja) * 1997-08-15 2001-09-18 オンコーメッド・インコーポレイテッド ヒトｂｒｃａ２遺伝子のコード配列半数型
US20090269814A1 (en) * 1998-05-22 2009-10-29 Murphy Patricia D Method of Analyzing a BRCA2 Gene in a Human Subject
US6051379A (en) * 1997-09-23 2000-04-18 Oncormed, Inc. Cancer susceptibility mutations of BRCA2
US6492109B1 (en) 1997-09-23 2002-12-10 Gene Logic, Inc. Susceptibility mutation 6495delGC of BRCA2
US6686163B2 (en) 1998-05-06 2004-02-03 Gene Logic Inc. Coding sequence haplotype of the human BRCA1 gene
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US7148016B1 (en) * 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
AUPQ421699A0 (en) * 1999-11-24 1999-12-16 University Of Western Australia, The Tumour suppressor factor
US20050013803A1 (en) * 2000-07-07 2005-01-20 Benjamin Thomas L. Diagnosing and treating cancer cells using mutant viruses
US20030157481A1 (en) * 2001-12-10 2003-08-21 Benjamin Thomas L. Diagnosing and treating cancer cells using T-HR mutants and their targets
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
EP1349924A2 (de) 2000-11-03 2003-10-08 Dana Farber Cancer Institute Zusammensetzungen und verfahren zur diagnose von krebsanfälligkeit und defekter dna reparaturmechanismen und behandlungen davon.
US6816789B2 (en) * 2001-04-19 2004-11-09 Varian, Inc. Method and system for analyzing chromatograms
WO2002099134A1 (en) * 2001-06-05 2002-12-12 Auckland Uniservices Limited Methods and compositions for assessment of pulmonary function and disorders
WO2003044212A2 (en) * 2001-11-16 2003-05-30 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate brca2 and methods of use
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
EP1896607A4 (de) * 2005-05-10 2009-12-16 Synergenz Bioscience Ltd Verfahren und zusammensetzungen zur beurteilung der lungenfunktion und von lungenerkrankungen
JP2008545390A (ja) * 2005-05-19 2008-12-18 シナージェンズ バイオサイエンス リミティド 遺伝的多型を用いた肺癌を発達させるリスクの評価方法
WO2006123954A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
WO2006123943A1 (en) * 2005-05-20 2006-11-23 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
PL2134876T3 (pl) * 2006-06-22 2014-10-31 Pomorski Univ Medyczny Określanie predyspozycji do raka piersi poprzez identyfikację kombinacji genotypu specyficznych wariantów genów CYP1B1, BRCA2 oraz CHEK2
WO2008021288A2 (en) 2006-08-11 2008-02-21 Johns Hopkins University Consensus coding sequences of human breast and colorectal cancers
US7993835B1 (en) 2007-05-11 2011-08-09 Myriad Genetics, Inc. BRCA2 mutations and use thereof
KR20160102081A (ko) 2008-08-10 2016-08-26 쿠아키니 메디컬 센터 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법
EP3075864A1 (de) * 2008-10-14 2016-10-05 Caris MPI, Inc. Gen und genexprimierte zielproteine zur darstellung von biomarkermustern und signatursets nach tumortyp
EP2350320A4 (de) * 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings Verfahren und systeme zur verwendung von exosomen zur bestimmung von phänotypen
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
US20130018700A1 (en) * 2011-07-14 2013-01-17 International Business Machines Corporation Optimizing product portfolios under customer choice
US20140222512A1 (en) * 2013-02-01 2014-08-07 Goodsnitch, Inc. Receiving, tracking and analyzing business intelligence data
US20140343982A1 (en) * 2013-05-14 2014-11-20 Landmark Graphics Corporation Methods and systems related to workflow mentoring
US10133996B2 (en) * 2014-04-22 2018-11-20 International Business Machines Corporation Object lifecycle analysis tool
CN104962613B (zh) * 2015-06-02 2019-12-03 南京医科大学 一种用于乳腺癌辅助诊断的突变基因及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
CA1188246A (en) 1981-08-31 1985-06-04 Jerry L. Gregory Immobilized microbe recycle apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4868105A (en) 1985-12-11 1989-09-19 Chiron Corporation Solution phase nucleic acid sandwich assay
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US5773278A (en) † 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
GB2307477B (en) * 1995-11-23 1997-10-22 Cancer Res Campaign Tech Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US6045997A (en) † 1995-11-23 2000-04-04 Duke University Materials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereof
US5879890A (en) † 1997-01-31 1999-03-09 The Johns Hopkins University APC mutation associated with familial colorectal cancer in Ashkenazi jews
WO1998049324A2 (en) † 1997-04-30 1998-11-05 Genzyme Limited Carbohydrate-deficient glycoprotein syndrome type i
CA2293674A1 (en) † 1997-06-04 1998-12-10 Egbert Bakker A diagnostic test kit for determining a predisposition for breast and ovarian cancer, materials and methods for such determination
US6376176B1 (en) † 1999-09-13 2002-04-23 Cedars-Sinai Medical Center Methods of using a major histocompatibility complex class III haplotype to diagnose Crohn's disease
BR0109192A (pt) † 2000-03-16 2003-05-27 Sucampo Ag Tratamento de hipertensão ocular e glaucoma.
AU2000243515A1 (en) † 2000-04-13 2001-10-30 Genaissance Pharmaceuticals, Inc. Association of beta2-adrenergic receptor haplotypes with drug response
US20060105403A1 (en) † 2001-06-13 2006-05-18 Venezia Nicole D Braca1/acc alpha molecular complexes, diagnostic and therapeutic applications

Also Published As

Publication number Publication date
NZ326525A (en) 1999-11-29
EP0785216A1 (de) 1997-07-23
AU1461597A (en) 1997-07-14
IL124620A0 (en) 1998-12-06
ATE230759T1 (de) 2003-01-15
DE69625678T2 (de) 2003-11-06
EP0785216B2 (de) 2006-06-07
US6033857A (en) 2000-03-07
DE69625678T3 (de) 2006-11-09
JP3455228B2 (ja) 2003-10-14
CA2239733C (en) 2001-04-03
NO982785D0 (no) 1998-06-17
CA2239733A1 (en) 1997-06-26
DE69625678D1 (de) 2003-02-13
WO1997022689A1 (en) 1997-06-26
EP0785216B1 (de) 2003-01-08
US6124104A (en) 2000-09-26

Similar Documents

Publication Publication Date Title
NO982785D0 (no) Kromosom 13-koblet brystkreftmottagelighetsgen
EP1260520A3 (de) Chromosom 13 verbundene Brustkrebsempfindlichkeitsgen BRCA2
WO1996005307A3 (en) 17q-linked breast and ovarian cancer susceptibility gene
WO1996005306A3 (en) In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
Berliner et al. Detection of a frequent restriction fragment length polymorphism in the human T cell antigen receptor beta chain locus. A potential diagnostic tool.
Lefèvre et al. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma
Adams et al. Role of genetic factors in drug-related autoimmunity
MX9701074A (es) Gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
Di et al. Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes
WO1998025125A3 (en) Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
WO2001085911A3 (en) Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes
DE69934107D1 (de) Isolierte sh3 gene, die mit myeloproliferativen erkrankungen und leukämie verbunden sind, und deren verwendungen
Skrzypczak et al. MYH gene status in polish FAP patients without APC gene mutations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application